Wearing-off effect of quarterly and monthly fremanezumab

Takeaway

  • Patients treated with quarterly or monthly fremanezumab did not experience a wearing-off effect towards the end of the dosing interval.

Why this matters

  • Fremanezumab, a fully humanized monoclonal antibody, is used as preventive treatment for migraines in adults and is approved for monthly and quarterly subcutaneous dosing.

  • As a wearing-off effect has been reported for other migraine treatments and considering the long dosing interval of fremanezumab it was important to investigate if reduced efficacy in the final weeks before the next scheduled dose also occurs with this drug.

  • This post hoc analysis of data from a Phase III study of fremanezumab provides evidence that patients with migraine treated with this drug do not experience a wearing-off effect.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.